July 30th, 2007 - Cambridge / Jerusalem - Antitope Ltd., inventors of the Composite Human AntibodyTM technology, announced a research and product development agreement with ProtAb Ltd. (a wholly-owned portfolio company of Hadasit Bio-Holdings Ltd, traded on the Tel Aviv Stock Exchange: HDST) for the generation of therapeutic antibodies. Under the research agreement Antitope will generate a humanized monoclonal antibody for the treatment of rheumatoid arthritis and other autoimmune diseases.
